Amarin (AMRN) submitted its supplemental new drug application (sNDA) for Vascepa on March 28th. Given the FDA review timeline, there are upcoming catalysts for this filing that could weigh heavily on … [Read more...] about INVESTOR ALERT: Why Amarin May Already Know Their Chances of Receiving Priority Review
pdufa
PDUFA Watch: Novartis’ Zolgensma (AVXS-101)
Novartis' PDUFA date is May 2019While approval may not have a significant impact on Novartis' price, a patterns suggests there may be money to be made on Ionis' stock The time is drawing nearer to … [Read more...] about PDUFA Watch: Novartis’ Zolgensma (AVXS-101)
Pdufa Watch
Nabriva's Hype It has been decades since the US has seen a new novel treatment in the antibiotics arena, creating positive sentiment surrounding the approval of Nabriva's Contepo (fosfomycin). … [Read more...] about Pdufa Watch
Shorts Fighting To Keep CPRX from Gaining Momentum-Insiders Aren’t Phased
After a little research it appears that shorts are working overtime to hold Catalyst Pharmaceuticals (Nasdaq: CPRX) under $3.0. Only 5 days ago we were at $3.20. A month ago and before the PDUFA date … [Read more...] about Shorts Fighting To Keep CPRX from Gaining Momentum-Insiders Aren’t Phased
Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
ACRX to Spike Monday off Favorable ADCOM Vote 10-3: How to Handle It
MS Money Moves Swing thesis for AcelRX Pharma (ACRX) published last week in our "Swing Alert"article played out nicely. ACRX spiked ~70% from $2.90 to $4.92 in the last 5 trading sessions. The upward … [Read more...] about ACRX to Spike Monday off Favorable ADCOM Vote 10-3: How to Handle It
VSTM Overaction to Black Box Label Creates Buying Opportunity
For months Verastem Oncology (VSTM) investors have been eagerly awaiting the FDA's decision on it's lead product Duvelisib; a PI3K-δ (delta) and PI3K-γ (gamma) inhibitor that was granted Orphan Drug … [Read more...] about VSTM Overaction to Black Box Label Creates Buying Opportunity
ADMP Poised For NDA Approval
On August 27th, 2018 MS Money Moves initiated coverage on Adamis Pharmaceuticals (ADMP). At the time it was trading at $2.85 per share. Our analysis of the company indicated that it was oversold and … [Read more...] about ADMP Poised For NDA Approval
Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
Today September 20th Galectin Therapeutics (NASDAQ: GALT) announced promising results from their phase 1b clinical trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial. … [Read more...] about Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
GR-MD-02: Keytrua’s Partner, Cancer’s Nemesis
Tumors excrete elevated level of galectin-3 Galectin-3 diminishes T-cells’ ability to kill tumor cells Galectin-3 aids in cancer progression GR-MD-02 is safe, effective, and … [Read more...] about GR-MD-02: Keytrua’s Partner, Cancer’s Nemesis
You must be logged in to post a comment.